GPA
ARNA

GSB Podium Advisors’s Arena Pharmaceuticals Inc ARNA Stock Holding History

GSB Podium Advisors’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,050
Closed -$55K – 6
2013
Q3 		$55K Buy
+1,050
New +$70.5K 4.48% 7

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

GSB Podium Advisors's ARNA Position: Q4 2013 in Review

GSB Podium Advisors sold out of Arena Pharmaceuticals Inc (ARNA) in Q4 2013, closing a stake of 1,050 shares — an estimated $55K sold.

GSB Podium Advisors first reported a position in ARNA in Q3 2013 and held it in 1 quarter. The position peaked at $55K in Q3 2013. 134 funds tracked by Wall St. Rank hold ARNA as of Q4 2013.

  • GSB Podium Advisors reported no remaining Arena Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • GSB Podium Advisors sold 1,050 Arena Pharmaceuticals Inc shares in Q4 2013, an estimated $55K.
  • GSB Podium Advisors first reported a position in Arena Pharmaceuticals Inc in Q3 2013 and held it in 1 quarter.
  • GSB Podium Advisors's Arena Pharmaceuticals Inc position peaked at $55K in Q3 2013.
  • 134 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q4 2013.

Based on GSB Podium Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.